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Abstract
Background: It is well known that many malignancies, including pancreatic cancer (PC), possess the ability to evade the
immune system by indirectly downregulating the mononuclear cell machinery necessary to launch an effective immune
response. This knowledge, in conjunction with the fact that the trancriptome of peripheral blood mononuclear cells has
been shown to be altered in the context of many diseases, including renal cell carcinoma, lead us to study if any such
alteration in gene expression exists in PC as it may have diagnostic utility.
Methods and Findings: PBMC samples from 26 PC patients and 33 matched healthy controls were analyzed by whole
genome cDNA microarray. Three hundred eighty-three genes were found to be significantly different between PC and
healthy controls, with 65 having at least a 1.5 fold change in expression. Pathway analysis revealed that many of these genes
fell into pathways responsible for hematopoietic differentiation, cytokine signaling, and natural killer (NK) cell and CD8+ T-
cell cytotoxic response. Unsupervised hierarchical clustering analysis identified an eight-gene predictor set, consisting of
SSBP2, Ube2b-rs1, CA5B, F5, TBC1D8, ANXA3, ARG1, and ADAMTS20, that could distinguish PC patients from healthy controls
with an accuracy of 79% in a blinded subset of samples from treatment naı ¨ve patients, giving a sensitivity of 83% and a
specificity of 75%.
Conclusions: In summary, we report the first in-depth comparison of global gene expression profiles of PBMCs between PC
patients and healthy controls. We have also identified a gene predictor set that can potentially be developed further for use
in diagnostic algorithms in PC. Future directions of this research should include analysis of PBMC expression profiles in
patients with chronic pancreatitis as well as increasing the number of early-stage patients to assess the utility of PBMCs in
the early diagnosis of PC.
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Introduction
Pancreaticcancer(PC)remainsalethalmalignancywithanoverall
five-year survival rate of only about 5% [1]. A significant contributor
to the poor prognosis of PC patients is the failure to detect the tumor
at an early and potentially resectable stage. It is estimated that only
8% of PC cases are diagnosed with tumors localized to the pancreas,
while only 15–20% are considered resectable. Further, of those
patients who have had their tumor resected, only 20% live more than
5 years post-diagnosis [2]. The most common cause of death post-
resection is distant metastases; local recurrence is rare. Although
studies showing prolonged survival in PC patients are rare, it is
unquestionable that early detectiona n dr e s e c t i o no fP C ,e s p e c i a l l yi n
a localized state, would likely yield a significant increase in survival.
Designing an early diagnostic test for PC however, presents a
particular challenge owing to the relative rarity of the disease and
the fact that the disease often remains asymptomatic until an
advanced stage. Ideally, an early diagnostic test for PC would be
minimally invasive, and relatively inexpensive, while being
sufficiently sensitive to identify all or most cases of PC. When
combined with a highly specific confirmatory test, it could
potentially permit the early identification of patients with
resectable disease.
CA19-9 is currently the only marker approved by the FDA for
use in PC. However, while CA19-9 is useful as a marker of disease
burden, it lacks both sensitivity and specificity (approximately 80%
and 73% respectively) as a diagnostic marker [3–8]. Nonetheless, it
remains the gold standard against which every potential biomarker
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have emerged which can potentially detect early stage PC either in
the tissues (MUC4, MUC1, CECAM1) or in blood (MIC-1,
NGAL, telomerase and microRNAs) [9]. However, none of these
potential biomarkers are free of significant imperfections, showing
sensitivities and/or specificities that are either poor or inconsistent
between studies. Thus, there is a clinical need for novel markers
for the early diagnosis of PC.
Peripheral blood mononuclear cells (PBMCs) comprise the
circulating mononuclear cells, including monocytes, T-cells, B-
cells, and natural killer (NK) cells, and have emerged in recent
years as surrogate markers of several diseases including inflam-
matory (e.g. preeclampsia, rheumatoid arthritis, and chronic
pancreatitis) and malignant (chronic lymphocytic leukemia and
renal cell carcinoma) diseases [10–14]. However, their role in the
detection and prognostication of solid tumors remains limited. In
the present study, we hypothesized that an alteration in the global
gene expression profile of PBMCs occurs in patients with PC and
identification of PC-specific gene subsets in PBMCs could be
potentially useful in the early detection of this malignancy.
Recent developments have permitted the development of gene
chips containing a set of disease specific genes for either the
diagnosis or predicting prognosis of several malignancies including
breast and esophageal cancers [15–18]. The results of our study
suggest that an eight-gene predictor set (selected from 383
differentially expressed genes out of 39,200 genes) can distinguish
between PC and healthy individuals with a sensitivity and
specificity of 83% and 64% respectively.
Materials and Methods
Study population
The study of blood-based biomarkers in PC was approved by the
Institutional Review Board (IRB) at the University of Nebraska
Medical Center (UNMC) (IRB number 209-00). Written informed
consent was obtained from all patients and controls before enrollment
into the study. For this study, 26 PC patients and 33 age, race, and
gender matched healthy controls were recruited. A total of 35 samples
were obtained from the PC and 33 from the healthy group. Baseline
demographic information for both groups is detailed in Table 1.
ThediagnosisofPCwasbased onapositivebiopsyofa pancreatic
massorametastaticlesion.ThePCpatientswerefurtherclassifiedas
localized (stage 1 and 2a) or non-localized (stage 2b and higher), pre-
or post-surgery, and pre- or post-chemotherapy. A patient was
classified as being post-surgery if they had undergone a pancreat-
icoduodenectomy before the sample was drawn. All other samples,
including samples from patients who never had surgery during the
course of their disease, were classified as pre-surgery. Any sample
drawn before the patient had undergone any chemotherapy for PC
was classified as pre-chemotherapy. If the patient had ever had
chemotherapy for PC, regardless of whether or not that patient was
undergoing chemotherapy at the time the sample draw, the sample
was classified as being post-chemotherapy. For patients in whom
multiple samples were drawn on different dates, all samples were
used in the data analysis unless explicitly stated in the results section.
PC staging was based on one of four criteria: 1) pathological
staging post-surgery, 2) MRI/CT/ultrasound staging, 3) endo-
scopic staging, or 4) biopsy of metastatic disease.
Isolation of total RNA from PBMCs
PBMCs were isolated from whole blood using the PharmLyse
RBC lysis solution (BD, San Jose, CA) according to the
manufacturer’s instructions. Total RNA was extracted using the
Qiagen RNAeasy RNA isolation kit (QIAGEN, Valencia, CA,
USA) and then converted to cDNA using the SuperScript II
cDNA synthesis kit (Invitrogen, Carlsbad, CA) according to a
previously published protocol [19].
cDNA microarray analysis of global gene expression
profile of PBMCs
Microarray analysis was performed by the UNMC microarray
core facility using established lab protocol on a Phalanx whole
genome cDNA microarray containing 30,275 features probing for
approximately 22,000 unique genes. A universal human reference
(Stratagene, Cat: 740000, Cedar Creek, TX) was used as the
reference against which all samples were normalized.
Statistical Analysis
Log2 transformation was applied to all ratios followed by
normalization to ‘‘center’’ each array using Lowess smoother
through BRB ArrayTools developed by Dr. Richard Simon and
Amy Peng [20]. Any gene in which the percent of spots missing or
filtered out exceeded 50% was excluded. Duplicate spots were not
averaged but treated as separate genes for analysis. Mixed effects
models were then used to determine which genes were significantly
differentially expressed between the PC and the healthy control
groups, allowing for a 10% false discovery rate. Diagnosis group
(cancer vs. normal) was included in the model as a fixed effect and
a random subject effect was also included to account for multiple
samples per person.
Hierarchical clustering analysis of the arrays based on similarity
of expression profiles was performed using the normalized and
log2-transformed data. Clustering was done using Gene Cluster
version 3.0, using the ‘‘centered’’ Pearson correlation similarity
metric and complete linkage clustering method, and visualized
using Java TreeView.
Validation of microarray data by Q-RT PCR
The microarray results were validated by quantitative real time
PCR (Q-RT PCR). All Q-RT PCR reactions utilized SYBR green
based chemistry. For validation, six of the most differentially
expressed genes: 3 up-regulated (ANKRD22, ANXA3, ARG1) and 3
down-regulated (FCER1A, GRAMD1C, and MS4A1) by microarray
were chosen. Validation was done in a randomly selected subset of
the original samples (submitted for microarray analysis) that
included nine healthy controls and twelve PC patients. The fold-
change in gene expression was determined by the 2
-DDCt method
using the same human reference RNA as that employed in the
microarray. To determine the correlation between the microarray
and Q-RT PCR results, we calculated the median fold change in
expression (for a given gene) for PC vs. healthy controls, and
compared it to the fold change seen by microarray to determine
whether the gene was still differentially expressed in the same
direction.
Correlation of gene signatures with clinicopathologic
characteristics in PC
To determine if there is the differential expression of genes in
PC patients correlates with patient characteristics, a mixed effects
model was applied to the PC samples that were grouped according
to the following criteria: surgical status (pre- vs. post-surgery),
chemotherapy status (pre- vs. post-chemotherapy), history of type-
II diabetes mellitus prior to the diagnosis of PC (present vs.
absent), location of the tumor (head vs. body/tail), and stage of PC
(localized vs. non-localized, and metastatic vs. non-metastatic).
Significant genes were chosen based on an allowable false
discovery rate of less than 10%. Stage 1a and 2a PC were
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considered non-localized, and stage 4 tumors were considered
metastatic. For two patients recruited into the study, information
on tumor stage, tumor location, and history of type-II diabetes
mellitus could not be obtained.
Identification of a gene predictor set that distinguishes
PC from healthy individuals
BRB-ArrayTools Version 3.8.0 was used to analyze all possible
combinations of the 21,671 valid genes identified by microarray to
determine whether a genetic signature could be identified that
would distinguish PC patients from healthy controls with the
optimum combination of sensitivity and specificity. The micro-
array data for 24 randomly chosen PC samples and 20 healthy
controls was entered into the analysis. Genes to be selected for the
predictor set were required to be significantly different between the
PC and healthy control groups with a significance level of
p#0.0001 and with a fold difference expression between the two
groups $1.5. Cross validation of the gene predictor set was
repeated 1 times K-fold (K=10). The gene predictor set arrived at
through these methods was analyzed by various methods,
including Compound Covariate Predictor, Diagonal Linear
Discriminant Analysis, 1-Nearest Neighbor, 3-Nearest Neighbors,
Nearest Centroid, Support Vector Machines, and Bayesian
Compound Covariate Predictor. Of these, the Compound
Covariate Predictor gave the best predictive capabilities using
the gene predictor set and consequently used.
Validation of the gene predictor set
Once the predictor set was established, it was validated in a
second set of randomly selected PC and healthy samples. The
statistician was blinded to the identity of the samples. Applying the
cut-off obtained through the Compound Covariate Prediction
method, the samples were classified as either ‘‘PC’’ or ‘‘non-PC’’.
The analyzer (M.B.) was then unblinded and the accuracy of the
prediction determined by comparison with the actual diagnosis.
We also applied the same equation to a subset of pre-
chemotherapy pre-surgical PC patients to determine the ability
of the predictor set to correctly classify patients into PC vs. non-
PC. This is important as the influence of chemotherapy and/or
surgery on the gene expression profile of PBMCs cannot be ruled
out. Further, the latter group of patients represents the ideal
patient population in whom the test, if validated would be applied
in a clinical setting.
Table 1. Demographics of PC Patients and Controls used in the study.
Characteristic PC Healthy Controls
Samples
Number of patients 26 33
Number of PBMC samples 35 33
Gender
Male 13 (50%) 6 (18.2%)
Female 13 (50%) 22 (66.7%)
Unknown 0 (0%) 5 (15.2%)
Age
Mean (6SD) 64.4 (69.0) 55.7 (66.1)
Unknown 0 (0%) 5 (15.2%)
Race
Caucasian 21 (80.8%) 25 (75.8%)
Non-Caucasian 3 (11.5%) 3 (9.1%)
Unknown 2 (7.7%) 5 (15.2%)
Stage at Diagnosis
Resectable (stage 1- 2a)-patients recruited into study 4 (15.4%) N/A
Resectable (stage 1-2a)-blood samples drawn 6 (17.1%) N/A
Non-resectable (stage 2b or higher)-patients recruited into study 20 (76.9%) N/A
Non-resectable (stage 2b or higher)-blood samples drawn 27 (77.1%) N/A
Stage unknown-patients recruited into study 2 (7.7%) N/A
Stage unknown-blood samples drawn 2 (5.7%) N/A
Surgical Status
Pre-surgical 23 (65.7%) N/A
Post-surgical 12 (34.3%) N/A
Chemotherapy Status
Pre-chemotherapy 15 (42.9%) N/A
Post- Chemotherapy 20 (57.1%) N/A
Undergoing Chemotherapy at time of Sample Collection 10 (28.6%) N/A
Abbreviations: PC, pancreatic cancer; PBMC, peripheral blood mononuclear cells.
doi:10.1371/journal.pone.0017014.t001
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After normalization and filtering of the microarray data, 21,671
genes remained for analysis. Of these, 383 genes were found to
have a significant differential expression between PC patients and
healthy controls (Table S1). Of these, 65 genes were observed to
have a differential expression $1.5-fold between the two groups
(Tables 2–3).
A hierarchical clustering of the microarray data identified two
clusters of samples, shown in Figure 1 and in dendrogram form in
Figure 2, a PC group and a healthy control group. Two PC
samples however clustered with the healthy controls, while one
healthy control fell into the cluster containing the majority (32/35)
of the PC samples. Additionally, the gene expression profile of one
PC sample did not cluster with either the healthy controls or the
other PC samples.
Q-RT PCR Validation
Six of the most differentially expressed genes (ANKRD22,
ANXA3, ARG1, FCER1A, GRAMD1C, and MS4A1) were chosen
for validation by Q-RT PCR in a randomly selected subset of 21
PBMC samples (comprised of 12 PC samples and 9 healthy
control samples from the original 68 used in the microarray). The
median fold expression for five of them was in the same direction
as that in the microarray, giving us a validation rate of 83%.
FCER1A was the only gene for which a positive correlation was not
obtained. The results are depicted in Table 4.
Correlation of PBMC expression profile with
clinicopathologic characteristics
To determine whether a correlation existed between the PBMC
gene expression profile in PC patients and clinically relevant
patient characteristics, we divided the PC samples based on
surgical status (23 pre-surgery vs. 12 post-surgery), history of
chemotherapy (15 pre-chemotherapy vs. 20 post-chemotherapy),
diagnosis of type-II diabetes mellitus prior to the diagnosis of PC
(14 with a positive history vs. 19 with a negative history), location
of the primary tumor (25 head vs. 8 body/tail), and stage of the PC
at diagnosis (6 localized (Stage 1/2A) vs. 12 non-localized non-
metastatic (Stage 2B/3) vs. 15 metastatic (Stage 4) PC). However,
we did not observe any significant difference in gene expression
between any of these patient groups applying the criterion of an
FDR ,10%.
Gene Predictor Set
We next investigated whether we could identify a minimal gene-
predictor set that would accurately discriminate PC cases from
healthy controls. To do this, 44/68 samples comprising 24 PC and
20 healthy control samples were randomly chosen. All 21,671
Table 2. Genes Shown to be at Least 1.5 Fold Upregulated in PBMCs of PC Patients.
Gene symbol Unique id FDR Fold-change (PC/HC) Gene Information and Normal Gene Function
TMEM22 PH_hs_0038059 0.069 4.812 Transmembrane protein 22, Function unknown
MMP8 PH_hs_0024515 0.076 2.351 Neutrophil protein used to degrade type I, II and III collagens
ARG1 PH_hs_0025817 0.021 2.106 Catalyzes the hydrolysis of arginine to ornithine and urea
DEFA4 PH_hs_0000344 0.086 2.098 A neutrophil protein thought to be involved in host defense
SLC27A3 PH_hs_0025689 0.039 2.024 Protein with acyl-CoA ligase activity for LCFA and VLCFA
USH1C PH_hs_0023496 0.086 2.022 May be involved in protein-protein interaction
FBXW12 PH_hs_0035757 0.067 1.893 Substrate-recognition component of SCF-type E3 ubiquitin ligase
CRISP3 PH_hs_0024631 0.027 1.891 A secreted protein found in the salivary gland, pancreas and prostate
USP30 PH_hs_0026074 0.084 1.819 Responsible for c-terminal deubiquitination
ANXA3 PH_hs_0021146 0.039 1.793 Important in cell growth/signaling and possibly anti-coagulation
HIST1H4I PH_hs_0029514 0.071 1.786 A member of the histone H4 family
PROS1 PH_hs_0003988 0.054 1.751 Helps to prevent coagulation and stimulates fibrinolysis
GYG1 PH_hs_0010438 0.015 1.722 Involved in glycogen anabolism
ANKRD22 PH_hs_0032205 0.063 1.676 Ankyrin repeat domain-containing protein 22
GADD45A PH_hs_0004630 0.025 1.596 Responds to environmental stresses through activation of p38/JNK
F5 PH_hs_0002589 0.010 1.587 Coagulation factor V which circulates in plasma
KIF15 PH_hs_0023756 0.062 1.577 A member of the kinesin-like protein family
ST14 PH_hs_0003679 0.031 1.551 Degrades extracellular matrix and may play a role in cancer invasion
HIST1H2BG PH_hs_0034684 0.072 1.546 A member of the histone H2B family
CLU PH_hs_0025525 0.038 1.545 A secreted protein of unknown function
C19orf59 PH_hs_0010615 0.093 1.523 Speculated to be involved in regulating mast cell differentiation
ATP9A PH_hs_0019278 0.053 1.512 Catalyzes ATP+H2O+phospholipid(In)=ADP+phosphate+phospholipid
FKBP5 PH_hs_0000782 0.046 1.511 Plays a role in immunoregulation, protein folding, and trafficking
ASGR2 PH_hs_0000166 0.092 1.510 Mediates endocytosis of plasma glycoproteins
SLC37A3 PH_hs_0025758 0.025 1.500 Sugar phosphate exchanger 3 (Solute carrier family 37 member 3)
Abbreviations: PC, pancreatic cancer; HC, healthy controls; PBMC, peripheral blood mononuclear cells; FDR, false discovery rate.
doi:10.1371/journal.pone.0017014.t002
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eight-gene predictor set was obtained and comprised of SSBP2,
Ube2b-rs1, CA5B, F5, TBC1D8, ANXA3, ARG1, and ADAMTS20.
Using the Compound Covariate Prediction Method (CCPM), this
predictor set gave a correct classification of PC vs. non-PC with an
accuracy of 73%, providing a sensitivity of 71% and a specificity of
75%. The weights given to each gene using CCPM were –4.97,
–4.83, –4.38, 4.43, 4.44, 4.53, 4.84, and 4.96 respectively with a
threshold value of 38.98 such that if Siwixi was . the threshold for
a sample it was predicted as being from a PC patient (where wi=
gene weight, xi= log2 gene expression intensity).
Validation of Gene Predictor Set
Using this eight-gene predictor set, classification of a sample as
being either PC or a healthy control was attempted in a blinded
manner using a sample set consisting only of the samples that were
Table 3. Genes Shown to be at Least 1.5 Fold Downregulated in PBMCs of PC Patients.
Gene symbol Unique id FDR Fold-change (PC/HC) Gene Information and Normal Gene Function
CCR5 PH_hs_0031237 0.021 0.66 A chemokine receptor expressed by T cells and macrophages
MTAC2D1 PH_hs_0003705 0.058 0.66 Tandem C2 domains
UBASH3A PH_hs_0010839 0.052 0.66 Promotes accrual of activated TCRs, EGFR and PDGFRB on cell surface
AKT3 PH_hs_0023601 0.013 0.66 An AKT serine/threonine kinase stimulated by PDGF, insulin, and IGF1
PRF1 PH_hs_0000291 0.097 0.65 Perforin, non-specifically lyses target cells
PKIA PH_hs_0020144 0.014 0.65 Potent competitive inhibitor of cAMP-dependent protein kinase activity
PLEKHA1 PH_hs_0014922 0.058 0.65 Binds specifically to PtdIns3,4P2, highly expressed in the pancreas
AQP3 PH_hs_0012796 0.003 0.65 A water channel protein that also transports of nonionic small solutes
CD1C PH_hs_0000177 0.027 0.65 Mediates the presentation lipid and glycolipid antigens to T cells
LRRC8C PH_hs_0002135 0.020 0.64 Leucine-rich repeat-containing protein 8C
GZMA PH_hs_0005055 0.027 0.64 A T cell and NK cell serine protease, possibly needed for target cell lysis
SH2D1A PH_hs_0009133 0.008 0.64 An inhibitor of SLAM self-association
PTPN4 PH_hs_0023771 0.010 0.63 Responsible for protein tyrosine dephosphorylation
CD5 PH_hs_0003778 0.028 0.63 May act as a receptor in regulating T-cell proliferation
PTPRCAP/
CORO1B
PH_hs_0009399 0.071 0.63 PTPRCAP is a regulator of T- and B-lymphocyte activation.
CORO1B regulates leading edge dynamics and cell motility in fibroblasts
FOSB PH_hs_0002354 0.001 0.63 Dimerizes with JUN proteins to form the AP-1 complex
LCK PH_hs_0000240 0.009 0.63 Essential to TCR-linked signal transduction and T-cell proliferation
LY9 PH_hs_0024619 0.015 0.63 May participate in adhesion between T lymphocytes and accessory cells
CD3G PH_hs_0000306 0.095 0.63 CD3-gamma, important in T-cell response to antigen recognition
LEF1 PH_hs_0003252 0.027 0.62 Regulates T-cell receptor alpha enhancer function
CA5B PH_hs_0039389 0.001 0.62 A zinc metalloenzyme that catalyzes the hydration of carbon dioxide
CD3D PH_hs_0005206 0.020 0.62 CD3-delta, important in T-cell response to antigen recognition
TRAT1 PH_hs_0031781 0.069 0.61 Stabilizes the TCR/CD3 complex at the surface of T-cells
LAT PH_hs_0026523 0.019 0.61 Recruits downstream proteins near the site of TCR engagement
KIAA0748 PH_hs_0002788 0.085 0.61 hypothetical protein LOC9840
CD3G PH_hs_0030882 0.004 0.60 CD3-gamma, important in T-cell response to antigen recognition
GPR115 PH_hs_0022672 0.059 0.60 An orphan G-protein coupled receptor 2
VSIG9 PH_hs_0033271 0.017 0.59 Thought to assist in regulating T-cell dependent B-cell responses
TRAV20/
TRDV2
PH_hs_0036583 0.068 0.58 T cell receptor alpha variable 20
T cell receptor delta variable 2
CD160 PH_hs_0004672 0.005 0.58 Associates with NK cell and CD8 T-cell cytolytic activity, found on T cells
DYRK2 PH_hs_0010380 0.004 0.57 Activates TP53 to induce apoptosis in response to DNA damage
EBI2 PH_hs_0040414 0.043 0.57 Predicted to encode a GPCR related to the thrombin receptor, found on B cells
MS4A1 PH_hs_0025653 0.015 0.56 Helps in the development and differentiation of B-cells into plasma cells
CCR3 PH_hs_0026576 0.061 0.55 A receptor for C-C type chemokines
EDG1 PH_hs_0009283 0.026 0.54 Possibly involved in regulating endothelial cell differentiation
FCER1A PH_hs_0000108 0.058 0.53 An IgE receptor found on Mast cells central to allergic disease
EBI2 PH_hs_0000092 0.001 0.52 Predicted to encode a GPCR closely related to the thrombin receptor
GRAMD1C PH_hs_0037695 0.009 0.52 GRAM domain containing 1C, Function unknown
Abbreviations: PC, pancreatic cancer; HC, healthy controls; PBMC, peripheral blood mononuclear cells; FDR, false discovery rate.
doi:10.1371/journal.pone.0017014.t003
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validation, using the equation derived above, the gene predictor
set accurately predicted the diagnosis of PC with 73% accuracy,
giving a sensitivity of 83% and a specificity of 64%.
In an attempt to further test the potential diagnostic utility of
this gene predictor set, a new subset of samples, comprising of 12
PC samples obtained from patients who were both pre-
chemotherapy and pre-surgery, along with an equal number of
randomly selected healthy controls, were again blinded and
analyzed to predict their classification. This time the eight-gene
predictor was able to correctly classify these samples 79% of the
time, giving an 83% sensitivity and 75% specificity of diagnosis.
Discussion
In recent years it has been repeatedly demonstrated that genetic
expression in PBMCs is altered in the context of malignancy
[13,14,21,22]. This observation of an altered PBMC genetic
expression profile in cancer patients was first reported in diffuse
large B-cell lymphoma and chronic lymphocytic leukemia and
later extended beyond hematological malignancies through the
analysis of PBMC expression profiling in patients with advanced
renal cell carcinoma (RCC) [13–14]. In both hematologic
malignancies and in RCC, it was reported that the variation in
gene expression between patients with disease and healthy controls
was much greater than the inter-sample variation observed for the
healthy patients alone, suggesting that PBMCs could be useful
surrogate markers with potential diagnostic and prognostic
applications in cancer. Further, in RCC, it was shown that an 8-
gene classifier set developed from the differentially expressed genes
could predict the diagnosis of malignancy with 100% accuracy
[14].
Recently, Huang et al. have reported that a differential gene
expression profile does exist in PBMCs of PC patients [22]. While
this study also used microarray and Q-RT PCR validation to
establish differential genetic expression in the peripheral blood of
PC patients, its purpose was to establish potential biomarkers that
could differentiate newly diagnosed diabetic patients with PC from
diabetics without PC. While the study authors reported that 48
genes were differentially expressed between PC patients and
healthy controls by microarray, only 8 samples were used in each
of the two groups and they provided no further information
regarding these genes. The smaller sample size and a lack of
blinded validation further contrast this study with the present
report. Additionally, we did not find any significantly differentially
expressed genes based on history of either prior surgery or
chemotherapy, history of type-II diabetes mellitus, or stage of PC
in our study. Importantly, the study by Huang et al. utilized
GAPDH as the housekeeping gene against which the expression of
every gene was normalized. In our study, however, we noted that
GADPH was one of the most significantly overexpressed genes in
PBMCs of PC patients. Upregulation of GAPDH has also been
reported in several malignancies including ovarian, thyroid,
hepatocellular and pancreatic cancers [23–26]. The choice of
the ideal internal reference gene in studies investigating potential
clinical biomarkers by microarray remains an important question
that will need to be addressed in future studies.
This present study represents the first in-depth analysis of the
transcriptome of PBMCs from patients with PC compared to
healthy controls, and only the third instance of such profiling for
solid tumors in general. Establishment of such differential
expression has the potential to yield a rich compendium of
potential genes for further pursuit as novel diagnostic or
therapeutic targets. Further, the gene networks identified in our
study offer novel insights into the disregulation of the immune
system in PC (Figure 3). With the fact that only 15–20% of PC
patients are diagnosed with resectable disease and given the
stubborn resistance of the malignancy to chemo and radiotherapy,
early detection of the disease offers the greatest hope for an
immediate impact on improving patient prognosis.
The potential for PBMC differential gene expression profiling,
or of a pre-determined gene predictor set established from it, to be
useful for early diagnosis of PC is theoretically quite high;
especially when it is considered that the two most likely
mechanisms underlying this differential expression are the
immune system’s recognition of the cancer and the evasion of
the immune system by the cancer. While other biomarkers, such as
CA19-9, are released from the cancer cells and thus rise with
Figure 2. Dendrogram of sample relatedness. A dendrogram of sample relatedness from the cluster analysis shown in Figure 1 using the
statistically significant differentially expressed genes. Samples clustered into main groups, aligning well with classification of PC or HC. PC PBMC
samples are indicated by grey bars while healthy PBMC samples are denoted by yellow bars.
doi:10.1371/journal.pone.0017014.g002
Figure 1. Global gene expression analysis in PBMCs from PC patients and healthy controls. Hierarchical cluster analysis of global gene
expression profile by cDNA whole genome microarray comparing healthy control and PC samples using all genes found to be statistically
differentially expressed between the two groups (FDR,0.10, n=383 genes). In no instance were samples pooled. Red indicates genes whose
expression is elevated relative to the universal human reference (used to normalize all arrays) and green indicates genes whose expression is
decreased relative to the universal human reference.
doi:10.1371/journal.pone.0017014.g001
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begin, at least partially, as soon as cancer immunogenicity or
immune evasion is established. Immune system evasion has been
shown to be initiated as early as pre-malignant disease in PC, thus
supporting the premise that analysis of differential gene expression
in immune cells may offer the ability to detect a neoplastic lesion
even before it gains invasive capabilities [27].
While this study itself does not attempt to look at the early
diagnostic capabilities of PBMCs, the results obtained from the
work are a necessary first step towards a multiplexed assay based
on alteration of gene expression in PC for potential application in
high-risk groups [28]. The fact that an 8-gene predictor set was
able to establish a sensitivity of 83% with a specificity of between
64 and 75% in a blinded set of samples is promising and will need
to be validated in a large sample set. While the number of samples
is too small to perform any further detailed analysis, the fact that
the sensitivity for the gene predictor set did not decrease when
applied to PC patients prior to chemotherapy or surgery points
toward the potential utility of this 8-gene predictor set in a
diagnostic setting, the main area in which CA19-9 is lacking [4–8].
Additionally, PBMC gene expression analysis is no more invasive
of a test than CA19-9, both being amenable to a simple
venopuncture, and the overall analysis need not be substantially
more expensive than current clinical methods for testing CA19-9.
Figure 3. Potential effect of the differential genetic expression of PBMCs. All genes shown were found to be down-regulated greater than
1.5 fold. The respective amount of differential expression per gene as well as the stated function can be found in Table 3. The differential expression
of these genes indicate that there is a global decrease in cell number, activation, and effectiveness of the adaptive immune system in patients with
PDAC that may have a significant effect on both their morbidity and mortality. Dashed lines indicate the association of cells while solid lines indicate
the differentiation or proliferation of a particular cell type. Numbers represent individual points of interaction between the genes and the immune
differentiation and response pathway: 1, Presentation of antigen to Th0 cells; 2, Differentiation of Th0 cells down the Th1 or Th2 pathway; 3, Immune
cell proliferation; 4, Stimulation of cytotoxic T-cell activity by Th1 cells; 5, Stimulation of humoral immunity by Th2 cells; 6, Recognition and response
to target cells by cytotoxic T lymphocytes (CTL); 7, Differentiation of naı ¨ve B-cells; 8, Lysis of target cells by CTLs. Letters represent individual cell
populations: a, Cytotoxic T-lymphocytes (CTL); b, B-cells. Decrease in genes associated with points a and b may represent a decrease in their
respective associated cell’s population.
doi:10.1371/journal.pone.0017014.g003
Table 4. Median fold change (PDAC/Normal) of selected
genes chosen for validation by Q-RT PCR.
Gene Name Microarray Q-RT PCR
ANKRD22 1.68 1.16
ANXA3 1.79 1.71
ARG1 2.11 1.95
FCER1A 0.53 1.24
GRAMD1C 0.52 0.49
MS4A1 0.56 0.62
Microarray results were validated by quantitative real time PCR (Q-RT PCR) using
SYBR green based chemistry. 3 genes shown to be up-regulated by microarray
(ANKRD22, ANXA3, ARG1) and 3 down-regulated (FCER1A, GRAMD1C, and
MS4A1) genes were validated in a randomly selected subset of samples that
included 9 healthy controls and 12 PC patients. The fold-change in gene
expression was determined by the 2
-DDCt method using the same human
reference RNA as the standard employed in the microarray. Correlation
between microarray and Q-RT PCR results were determined through calculation
of the median fold change for the PDAC and healthy samples by Q-RT PCR and
comparing it to the fold change seen by microarray to determine whether the
gene was differentially expressed in the same direction using both methods.
doi:10.1371/journal.pone.0017014.t004
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could be accomplished through the use of mini-cDNA microarray
chips or through multiplex PCR reactions, both of which are
clinically viable and would be fairly simple to add to the repertoire
of tests provided by a standard clinical lab.
Beyond the diagnostic potential of this PBMC differential
expression profile, the normal functions and direction of
differential expression of each of the genes, especially the 65 that
were $1.5 fold differentially expressed, hints at potential
pathophysiologic mechanisms. 18/65 genes have the potential to
directly decrease T-cell proliferation, T-cell receptor signaling, or
cytotoxic T-lymphocyte (CTL) cytotoxicity while four can directly
modulate a decrease in B-cell activation/differentiation or signal a
decrease in the number of circulating B-cells. Three of the genes
can directly decrease the cytotoxicity of NK cells, and two can
decrease macrophage response. Taken together, the results of our
study suggest that PC is characterized by a significant decrease in
the ability of the immune system to respond to non-self antigens,
including tumor associated antigens, as summarized in Figure 3. A
partial hint about the mechanisms underlying this immune
compromise may come from the observed upregulation of
ARG1, observed to be upregulated more than 2-fold in PBMCs
of PC patients. An expression of ARG1 is closely associated with
an increase in the presence of myeloid derived suppressor cells
(MDSCs) [29]. MDSCs are classically known to decrease CTL
response, mostly through destabilization of T-cell receptors and
decreased expression of certain CD3 subtypes, ultimately leading
to CTL apoptosis. However, MDSCs are known to specifically
cause the down regulation of CD3Z, which was not shown to be
differentially expressed in PBMCs analyzed in this study [29].
Additionally, MDSCs are known to cause a funneling of the
immune system away from cellular immunity and toward humoral
and allergic-response immunity, a property that is not clearly
represented in the PBMC differential expression data. Conversely,
it appears (from the alteration in gene expression) that the number
of circulating B-cells is decreasing while both FCER1A, a receptor
central to allergic response, and MS4A1, which plays a role in B-
cell to plasma cell differentiation, are down regulated. Thus, while
MDSCs may play a role in modulating the differential expression
seen in PBMCs of PC patients, they likely operate in concert with
other mechanisms to affect a down-regulation of both the body’s
cellular and humoral immune response machinery.
A comparison of the gene expression profile observed in our
study with that reported in other diseases revealed little similarity
with other benign (pre-eclampsia, rheumatoid arthritis (RA), and
chronic pancreatitis (CP)) and malignant diseases (RCC). In total,
6 genes (CD160, GOLGA8B, RABGAP1L, MMP8, CRISP3, and
ARG1) that were shown to be differentially expressed in PBMCs of
patients with pre-eclampsia were also differentially expressed in
PBMCs of PC patients, with 4 (CD160, MMP8, CRISP3, and
ARG1) being differentially expressed in the same direction (1%
commonality) [10]. Twelve genes (BTG2, CCND3, CD151, CD7,
CLU, CTSB, KLRK1, SPN, GSTO1, PCMT1, PRDX6, and PRF1)
that were shown to be differentially expressed in PBMCs of
patients with RA were also differentially expressed in PBMCs of
PC patients, 8 of which (CCND3, CD151, CLU, CTSB, GSTO1,
PCMT1, PRDX6, and PRF1) were in the same direction (2%
commonality) [11]. Two genes (PDE3B and GADD45a) found to
be differentially expressed in PBMCs of CP patients were also
differentially expressed in PBMCs of PC patients, neither of which
being differentially expressed in the same direction (0% common-
ality) [12]. However, there was no similarity in the list of
significantly differentially expressed genes between PC and RCC
[14]. These results strongly suggest that the gene expression
observed in the present study is highly specific to PC, and thus
increases the potential applicability of differential expression
profiling of PBMCs as a diagnostic tool in PC.
To investigate the possibility that the gene expression profile in
PBMCs is a reflection of the genes expressed in the PC tissues
itself, we also investigated if there was a similarity between the
differentially expressed genes identified in our study and those
identified by microarray analysis in pancreatic primary tumors. In
total it was found that, of the 383 differentially expressed genes
found in PBMCs of PC patients, only 4 (ADAM9, IMP3, BTG2,
and G6PD) were also shown to be differentially expressed in PC
primary tissues, with 2 (ADAM9 and BTG2) being differentially
expressed in the same direction (0.5% commonality) [30]. Thus it
appears that, in general, the gene expression in PBMCs does not
mimic that in the primary tumor.
Further, if circulating tumor cells from the pancreas were the
cause of the differential expression profile seen in this study, it would
be expected that genes normally expressed in pancreatic cells but
not peripheral blood cells would be identified by microarray. While
this was the case for USH1C, CRISP3,a n dUSP30, all genes that are
expressed at low to moderate levels in the pancreas but not
expressed normally in the peripheral blood, PLEKHA1, a gene that
is normally highly expressed in the pancreas but only expressed at
very low levels in the peripheral blood, was shown to be down
regulated in our samples, adding to the evidence that the differential
expression we report truly is from PBMCs.
In conclusion, we have shown that a differential gene expression
profile exists in PBMCs of patients with PC. Further, an 8 gene
classifier set has been established which provides, in a blinded
subset of our samples, an improved sensitivity over CA19-9 with a
similar specificity [3,4,6,28]. Significantly, there was no decrease
in sensitivity when employing samples from patients prior to any
form of chemotherapy or surgery. Comparison with other studies
points toward this differential expression profile as being specific to
PBMCs and particularly to PC. Additionally, the differential gene
expression seems to represent a systemic compromise of both
cellular and humoral immunity, although it does not point toward
one particular underlying mechanism.
Based on these results, future research is needed to establish the
various mechanisms behind PC-induced differential PBMC
genetic expression and how much effect this differential expression
actually has on the body’s immunologic capabilities. Further, the 8
gene classifier set must be tested in an expanded set of both healthy
controls and PC patients as well as in a set of non-PC patients with
benign/malignant disease to clarify its sensitivity and specificity.
PC sample selection for such a study should be biased toward early
stage patients to elicit the diagnostic capabilities of PBMC
differential expression in the patient population in which it has
the greatest likelihood of having a positive impact on patient
outcome. Due to the difficulty of attaining ample specimens from
early stage patients, preliminary study of early stage PC diagnosis
through PBMC expression analysis may be first carried out in a
spontaneous PC murine model which recapitulates the preneo-
plastic and early neoplastic processes seen in human PC as a proof
of concept [31,32]. Upon conclusion of such a murine study,
resources could then be expended in the recruitment and testing of
enough early stage human PC subjects for ample analysis to be
conducted. Once PBMC expression has been diagnostically
validated in an expanded sample set, the gene set could also be
used to characterize potential prognostic abilities of the PBMC
differential expression in PC.
Though further studies are necessary to contingently state the
diagnostic and prognostic potential of PBMC gene expression
profiling in general and of the 8 gene PC classifier set in particular,
Transcriptional Profiling of PBMCs in PC
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peripheral blood mononuclear cells to be highly efficacious tools for
improving the prognosis of one of the world’s deadliest cancers.
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